Karus Therapeutics CEO Simon Kerry discusses the company's focus on PI3 Kinase and HDAC6 inhibitor programmes.




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Karus Therapeutics CEO Simon Kerry discusses the company's focus on PI3 Kinase and HDAC6 inhibitor programmes.
Released on: July 17, 2013. © PharmaTelevision Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Simon Kerry the CEO of the Oxfordshire based company Karus Therapeutics, talks with Fintan Walton about the company's work to develop innovative medicines for the treatment of inflammatory disease and cancer.
  • Summary
  • Transcript
  • Participants
  • Company
Simon Kerry the CEO of the Oxfordshire based company Karus Therapeutics, talks with Fintan Walton about the company's work to develop innovative medicines for the treatment of inflammatory disease and cancer.
Simon Kerry the CEO of the Oxfordshire based company Karus Therapeutics, talks with Fintan Walton about the company's work to develop innovative medicines for the treatment of inflammatory disease and cancer.
Simon Kerry
Karus Therapeutics
Karus Therapeutics
The Company, led by a highly experienced management team, has a track record of scientific excellence in small molecule drug discovery. This has produced therapeutic programmes with the potential to be either first- or best-in-class agents for the treatment of inflammatory disease and cancer. These innovative programmes are underpinned by a broad intellectual property portfolio. Karus operates an outsourced business model: retaining drug design, experimental chemistry and in vitro biology research in-house, whilst outsourcing a significant proportion of its R&D activities to a network of internationally-recognised CROs. This approach has allowed Karus to remain capital efficient and flexible whilst advancing multiple R&D programmes through key value inflection points. Karus Therapeutics has a history of strong financial management and is backed by some of the biotech industry’s most experienced investors. By focusing its financial resources on creating value in its therapeutic programmes, the company has developed a strong track-record of delivering key R&D goals on time and to budget.